Steven De Maat

Utrecht, UT 3584CH, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 47 publications

Author Correction: Directing HIV-1 for degradation by non-target cells, using bi-specific single-chain llama antibodies.

Author Correction: Directing HIV-1 for degradation by non-target cells, using bi-specific single-chain llama antibodies.

Journal: Scientific reports

Published: April 28, 2025

Plasmin-cleaved von Willebrand factor as a biomarker for microvascular thrombosis.

Plasmin-cleaved von Willebrand factor as a biomarker for microvascular thrombosis.

Journal: Blood

Published: May 30, 2023

Insights in the Prothrombotic Changes After Implantation of a Left Ventricular Assist Device in Patients With End-Stage Heart Failure: A Longitudinal Observational Study.

Insights in the Prothrombotic Changes After Implantation of a Left Ventricular Assist Device in Patients With End-Stage Heart Failure: A Longitudinal Observational Study.

Journal: ASAIO journal (American Society for Artificial Internal Organs : 1992)

Published: February 02, 2023

Restriction of C1-inhibitor activity in hereditary angioedema by dominant-negative effects of disease-associated SERPING1 gene variants.

Restriction of C1-inhibitor activity in hereditary angioedema by dominant-negative effects of disease-associated SERPING1 gene variants.

Journal: The Journal of allergy and clinical immunology

Published: January 10, 2023

Factor XII Explored with AlphaFold - Opportunities for Selective Drug Development.

Factor XII Explored with AlphaFold - Opportunities for Selective Drug Development.

Journal: Thrombosis and haemostasis

Published: September 27, 2022

VWF-targeted thrombolysis to overcome rh-tPA resistance in experimental murine ischemic stroke models.

VWF-targeted thrombolysis to overcome rh-tPA resistance in experimental murine ischemic stroke models.

Journal: Blood

Published: March 17, 2022

Directing HIV-1 for degradation by non-target cells, using bi-specific single-chain llama antibodies.

Directing HIV-1 for degradation by non-target cells, using bi-specific single-chain llama antibodies.

Journal: Scientific reports

Published: February 03, 2022

A reactive center loop-based prediction platform to enhance the design of therapeutic SERPINs.

A reactive center loop-based prediction platform to enhance the design of therapeutic SERPINs.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: September 24, 2021

Targeted SERPIN (TaSER): A dual-action antithrombotic agent that targets platelets for SERPIN delivery.

Targeted SERPIN (TaSER): A dual-action antithrombotic agent that targets platelets for SERPIN delivery.

Journal: Journal of thrombosis and haemostasis : JTH

Published: July 23, 2021

VhH anti-thrombomodulin clone 1 inhibits TAFI activation and enhances fibrinolysis in human whole blood under flow.

VhH anti-thrombomodulin clone 1 inhibits TAFI activation and enhances fibrinolysis in human whole blood under flow.

Journal: Journal of thrombosis and haemostasis : JTH

Published: June 06, 2021

Microlyse: a thrombolytic agent that targets VWF for clearance of microvascular thrombosis.

Microlyse: a thrombolytic agent that targets VWF for clearance of microvascular thrombosis.

Journal: Blood

Published: March 19, 2021

Nanomedicine platform for targeting activated neutrophils and neutrophil-platelet complexes using an α1-antitrypsin-derived peptide motif.

Nanomedicine platform for targeting activated neutrophils and neutrophil-platelet complexes using an α1-antitrypsin-derived peptide motif.

Journal: Nature nanotechnology

Published: February 21, 2021

Showing 1-12 of 47

Last Updated: 09/26/2026